A profile of the live biotherapeutic product RBX2660 and its role in preventing recurrent Clostridioides difficile infection

被引：11

作者：

Chopra, Teena ^{[1
,2
,3
]}

机构：

[1] Detroit Med Ctr, Div Infect Dis Infect Prevent Epidemiol & Antibiot, Detroit, MI 48201 USA

[2] Wayne State Univ, Detroit, MI 48202 USA

[3] Vibra Hosp, Infect Prevent Epidemiol & Antibiot Stewardship, 4201 St Antoine, Detroit, MI 48201 USA

来源：

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2023年 / 21卷 / 03期

关键词：

Live biotherapeutic; recurrent CDI; sustained clinical response; clostridioides difficile; microbiome; FECAL MICROBIOTA TRANSPLANTATION; TREATMENT STRATEGIES; VANCOMYCIN; UPDATE; COMPLICATIONS; METRONIDAZOLE; COLONIZATION; METAANALYSIS; GUIDELINES; DIAGNOSIS;

D O I：

10.1080/14787210.2023.2171986

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

IntroductionClostridiodes difficile infection (CDI) is a life-threatening illness that has been labelled as an urgent threat by the Centers for Disease prevention (CDC).Areas CoveredRBX2660, a live biotherapeutic product offers a very promising treatment option for patients with recurrent Clostridiodes difficile infection(rCDI). RBX2660 restores the healthy gut microbiome and shows clinically meaningful benefits for patients suffering from rCDI. Safety, efficacy, and tolerability of RBX2660 have been thoroughly assessed .Expert OpinionAn FDA-approved, standardized, and accessible microbiota restoration product like RBX2660 would provide a new option for patients in need of treatment for rCDI by breaking the cycle of disease recurrence.

引用

页码：243 / 253

页数：11

共 83 条

[1] A Review of Clostridioides difficile Infection and Antibiotic-Associated Diarrhea [J].